BioCode® STI + Resistance Panel (RUO)

Optimize your STI research testing with a reliable, accurate, and sensitive molecular STI + Resistance Panel

BioCode® STI + Resistance Panel (RUO)
  • Qualitative assay for use on the MDx-3000 System
  • Single Reaction Multiplex Assay
  • Assesses specific mutations associated with macrolide and fluoroquinolone resistance
BioCode® STI + Resistance Panel (RUO)
Chlamydia trachomatis (CT)
BioCode® STI + Resistance Panel (RUO)
Trichomonas vaginalis (TV)
BioCode® STI + Resistance Panel (RUO)
Neisseria gonorrhoeae (NG)
BioCode® STI + Resistance Panel (RUO)
Mycoplasma genitalium (MG)

The BioCode® STI + Resistance Panel (RUO) is a multiplex nucleic acid amplification test intended for research use only. It is specially designed for utilization with the BioCode® MDx-3000 Instrument. This qualitative panel is capable of the simultaneous detection and identification of nucleic acids from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), Mycoplasma genitalium (MG) as well as macrolide-resistant and fluoroquinolone-resistant single nucleotide polymorphism (SNP) mutations. The test employs a single multiplex reaction allowing for the detection and differentiation of all targeted pathogens, antimicrobial resistance for NG and MG, as well as the DNA extraction control for each sample.

Product Details Targets:

  • Chlamydia trachomatis (CT)
  • Neisseria gonorrhoeae (NG)
  • Mycoplasma genitalium (MG)
  • Trichomonas vaginalis (TV)
  • SNPs associated with fluoroquinolone resistance in NG
  • SNPs associated with fluoroquinolone resistance and macrolide resistance in MG

Antibiotic Resistance Mutations detected by STI + Resistance Panel (RUO)

Antimicrobial Drug Class Organism Gene Mutation
Fluoroquinolones Mycoplasma genitalium  parC G248T (S83I)
Neisseria gonorrhoeae gyrA C271 (S91 WT*)
C271T (S91F)
Macrolides Mycoplasma genitalium 23S rRNA A2058C


BioCode® STI + Resistance Panel (RUO)

STI Summary

The global prevalence of sexually transmitted infections (STIs) exceeds 1 million new cases daily, with the majority being asymptomatic. Annually, this totals around 374 million new infections, encompassing common curable STIs such as chlamydia, gonorrhea, trichomoniasis, and Mycoplasma genitalium (MG). In addition to these, the detection of NG fluoroquinolone resistance marker and MG macrolide and fluoroquinolone resistance markers is crucial. These infections and resistance markers can lead to complications such as cervicitis, urethritis, preterm labor, pelvic inflammatory disease (PID), and heightened vulnerability to HIV. Consequently, accurate detection of these prevalent STIs and resistance markers is crucial for clinical researchers to comprehend outbreaks and disease origins.

Product Configuration – 96 Reactions

Part number Component


14-M0001 BioCode® Master Mix 2.5X 500 µL (2 vials)
24-S0017 BioCode® STI + Res. Panel (RUO) Primer Mix 2.5X

500 µL (2 vials)

23-D0001 BioCode® DNA-IC T4 Phage concentration varies per lot

500 µL (2 vials)

23-S0016 BioCode® STI + Res. Panel (RUO) BMB-Probe Mix 100 BMB/μL 6 mL (1 vial)
Part number Component


63-S0001 BioCode SA-PE Mix 50 µg/mL 450 µL (8 vials)
44-B0003 BioCode Buffer A 1X

1 L (1 bottle)

BioCode® STI + Resistance Panel (RUO)
Contact Us Today!

Want More Information About the BioCode® STI + Resistance Panel (RUO)?

For Research Use Only. Not for use in diagnostic procedures.


Sexually transmitted infections (STIs) (

Centers for Disease Control and Prevention (